ArticleEmerging infectious diseases2004
SARS coronavirus detection.
Article in Emerging infectious diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Diagnostics of SARS-CoV-2 infection using electrical impedance spectroscopy with an immunosensor to detect the spike protein.Talanta · 2022Article
- Nucleic Acid Testing of SARS-CoV-2.International journal of molecular sciences · 2021Review
- Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.Journal of computational chemistry · 2021Article
- Sample pooling as a strategy for community monitoring for SARS-CoV-2.Scientific reports · 2021Article
- Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures.Reviews in medical virology · 2020Review
- Currently used nucleic acid amplification tests for the detection of viruses and atypicals in acute respiratory infections.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2007Review
- SYBR Green real-time reverse transcription-polymerase chain reaction assay for the generic detection of coronaviruses.Archives of virology · 2007Article
- Use of dual TaqMan probes to increase the sensitivity of 1-step quantitative reverse transcription-PCR: application to the detection of SARS coronavirus.Clinical chemistry · 2005Article
- Rapid identification of emerging pathogens: coronavirus.Emerging infectious diseases · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed a set of three real-time reverse transcription-polymerase chain reaction (PCR) assays that amplify three different regions of the SARS-associated coronavirus (SARS-CoV), can be run in parallel or in a single tube, and can detect <10 genome equivalents of SARS-CoV. The assays consider all currently available SARS-CoV sequences and are optimized for two prominent real-time PCR platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.